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The liver is an important contributor to the human immune system and it plays a
pivotal role in the creation of both immunoreactive and tolerogenic conditions. Liver
transplantation provides the best chance of survival for both children and adults with
liver failure or cancer. With current demand exceeding the number of transplantable
livers from donors following brain death, improved knowledge, technical advances
and the desire to prevent avoidable deaths has led to the transplantation of organs
from living, ABO incompatible (ABOi), cardiac death donors and machine based organ
preservation with acceptable results. The liver graft is the most well-tolerated, from an
immunological perspective, of all solid organ transplants. Evidence suggests successful
cessation of immunosuppression is possible in ∼20–40% of liver transplant recipients
without immune mediated graft injury, a state known as “operational tolerance.” An
immunosuppression free future following liver transplantation is an ambitious but perhaps
not unachievable goal. The initial immune response following transplantation is a sterile
inflammatory process mediated by the innate system and the mechanisms relate to
the preservation-reperfusion process. The severity of this injury is influenced by graft
factors and can have significant consequences. There are minimal experimental studies
that delineate the differences in the adaptive immune response to the various forms
of liver allograft. Apart from ABOi transplants, antibody mediated hyperacute rejection
is rare following liver transplant. T-cell mediated rejection is common following liver
transplantation and its incidence does not differ between living or deceased donor grafts.
Transplantation in the first year of life results in a higher rate of operational tolerance,
possibly due to a bias toward Th2 cytokines (IL4, IL10) during this period. This review
further describes the current understanding of the immunological response toward liver
allografts and highlight the areas of this topic yet to be fully understood.
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INTRODUCTION
At present, orthotopic liver transplantation (OLT) is the
only effective treatment option for many conditions (1).
Unfortunately the demand for organs exceeds the supply, each
year in the United Kingdom ∼15% of patients awaiting a liver
transplant either die or are delisted due to disease progression
(2). Improvements in surgical technique, graft preservation
techniques, perioperative care and immunosuppression has
resulted in better short term graft function and patient survival
(1). The detrimental effects of long term immunosuppression in
regards to malignancies, metabolic disturbances, cardiovascular
disease, renal failure and opportunistic infections are well-
recognized (3, 4). These contribute significantly to the longer
term morbidity and mortality in transplant patients (5, 6).
The withdrawal of immunosuppression would eliminate these
complications and is therefore highly desirable (7). The term
“operational tolerance” implies a state of stable graft function
following cessation of immunosuppressive medications and
without evidence of rejection or graft injury (6). Operational
tolerance is known to occur spontaneously following OLT
more frequently than any other solid organ transplant (8).
Immunosuppression withdrawal trials suggest that the rate of
spontaneous operational tolerance may be as high as 40% in
adults and 60% in pediatric patients post OLT (4, 9). Research
focused on detecting biomarkers that identify patients who
have a higher probability of developing operational tolerance
are ongoing, as this would allow an expedited withdrawal of
immunosuppression (10). However, a major aim in the field
of transplantation is the development of tolerance inducing
therapies. Therapeutic administration of interleukin-2 (IL-2),
Regulatory T cells (Tregs), and dendritic cells (DC) are all being
investigated, some of which are in phase II clinical trials. Further
advancement in this area requires a detailed understanding of
the immunophysiology of the liver and the interaction with the
systemic immune system.
The allograft implanted during OLT can be from either a
living or deceased donor. Procurement of a deceased individuals
organs can occur following brain death (DBD) or cardiac death
(DCD) and the organ can be split between two recipients
depending on the volume of parenchyma required. Deceased
donors are scarce in many countries and implanting organs
from different ABO blood groups may be the only option
to save a recipient’s life, this is known as ABO incompatible
(ABOi) liver transplantation. Early reports of ABOi OLT
utilizing conventional immunosuppressive regimes and deceased
donors yielded significantly inferior results (11). However,
the introduction of modern therapies such as rituximab, a
chimeric monoclonal antibody against the protein CD20 on
B lymphocytes, has enabled living donor ABOi OLT to be
common practice in many countries with equivalent results
to conventional living donation (11). Liver transplantation for
pediatric patients is more challenging due to lack of size matched
donors. Pediatric patients most commonly receive a segmental
graft that could be from a split, reduced size or living donor liver
transplant (12). It is likely that variations in both the graft types
and indications for OLT influence the immune response elicited.
Understanding these in detail will allow further refinement of
immunosuppressive regimes and tolerance inducing therapies.
METHODS
Relevant existing publications for this narrative review were
identified by searching the Pubmed, EMBASE and Medline
databases. The search was limited to the English language, but
no other filters were utilized. The following terms were utilized
(in a variety of combinations); liver, transplant, immune response,
innate, acquired, cell, antibody, rejection, ischaemia reperfusion,
cadaveric, living donor, ABO incompatible, pediatric, pediatric.
Any additional publications relevant to this review were then
identified by manually searching article reference lists.
IMMUNE FUNCTION OF THE LIVER
The liver is one of the two organs in human body with
a dual blood supply, deriving blood from both arterial and
portal venous blood. Therefore, it is exposed to both systemic
and enterically derived pathogens (13). Portal venous blood
delivers essential gut derived nutrients to the liver, however
it also contains a significant volume of foreign antigens (13).
Once a pathogen breaches our first defensive barrier, the
intestinal epithelium, it will travel to the liver and therefore
this organ is essential in the defense against harmful pathogens
(14). However, unrestrained immune activation against non-
pathogenic foreign antigens would have a detrimental result.
The liver has a unique “tolerogenic” property which prevents
this occurring. A large population of immune cells reside in
the liver including macrophages (Kupffer cells), lymphocytes
and dendritic cells. In addition, both the hepatic stellate cells
(HSCs) and hepatocytes have immune functionality. Under
certain inflammatory conditions, hepatocytes can express MHC
II molecules and along with HSCs have been shown to interact
with lymphocytes (13). The immune surveillance and pathogen
clearance within the liver occurs predominantly at the hepatic
sinusoids (14).
Systemic infection has a significant effect on the liver. Sepsis
is known to induce changes in gene and protein expression
and this alteration in hepatocellular function is known as the
acute phase response. This response is triggered by IL-6 and
IL-1 from monocytes and stimulates hepatocytes to release
numerous acute phase proteins (APPs) (14). A number of these
proteins then proceed to augment the systemic immune system
by opsonising, further cellular activation or via direct action of
complement (14). APPs have a further role in the abrogation
of the immune response to prevent tissue injury from an over
response (15). It has been shown that APPs such as serum
amyloid A and Cxc11/KC result in the mobilization of myeloid
derived suppressor cells (MDSCs) which suppress inflammation
and T cell responses in particular (15). Bacteraemia is reported
to be ten times more common in patients with cirrhosis and it
is associated with a fourfold increase in mortality in comparison
to those without cirrhosis (14, 16). An imbalance of both
the defense mechanisms and counterregulatory responses are
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likely contributory to the susceptibility of these patients to life
threatening sepsis.
The liver is also a target of multiple autoimmune diseases.
Autoimmune liver disease (AILD) is comprised of autoimmune
hepatitis (AIH), primary biliary cirrhosis (PBC), and primary
sclerosing cholangitis (PSC). AIH results from a T cell mediated
insult on autoantigens and causes a chronic hepatitis with
an interface and lobular hepatitic component, however the
portal/interface component usually predominate (17). A subset
of T-cells, known as Tregs (CD4pos, CD25high, CD127LOW,
FoxP3pos), are key components of the immunosuppressive arm
of the immune system, suppressing effector cell activity and
restoring immune homeostasis. Multiple immunosuppressive
mechanisms have been attributed to Tregs such as the secretion
of anti-inflammatory cytokines and inhibitor molecules (e.g.,
CTLA4), depletion of crucial growth factors, disruption of
effector cell metabolism by promoting the accumulation of
adenosine nucleosides, consuming scarce amino acids and also
by direct cytotoxic killing of effector cells (18). The number
and function of Tregs are reduced in AIH, giving rise to
the theory of unchecked or un-inhibited effector cell activity
perpetuating the inflammatory cascade. AILD and liver allograft
rejection both rely on leukocyte recruitment to the liver, and
subsequent migration from the vasculature into the tissue. In
most tissues, migration across the vascular endothelium occurs at
post capillary venules (19). However, a study utilizing intravital
microscopy demonstrated that in 80% of leukocytes adhere to
the endothelium in the hepatic sinusoids and this is where the
majority of leukocyte extravasation occurs in the liver (19, 20).
Shear stress in the sinusoids in low and therefore the “rolling”
process described for leukocyte extravasation is not required
(19). Recruitment and adhesion of leukocytes is enhanced by
hepatic sinusoidal endothelium expressing peptide molecules
vascular adhesion protein 1 (VAP-1), VCAM-1, ICAM-1, CD44
(19). The recruitment of lymphocytes (in particular Th2) to
the liver is enhanced by VAP-1. An additional molecule known
as the common lymphatic endothelial and vascular endothelial
receptor 1 has been demonstrated to recruit Tregs to the liver and
promote transendothelial migration (19, 21). These recruitment
mechanisms used by the liver are preserved after transplantation
(19). The grafts endothelial cells are the first donor cells to
encounter recipient leukocytes and their activation is likely an
early event that leads to immune cell migration into the graft (22).
A hepatic allograft has immunoprotective benefits. The
frequency of renal allograft TCMR is significantly lower in
combined liver-kidney recipients in comparison to kidney
alone recipients (23). In addition, less frequent and severe
episodes of renal allograft rejection have been demonstrated
when kidney transplants occurred in patients with previous liver
transplants (24) Similar immunoprotective benefits were less
pronounced when renal transplants followed heart and lung
transplantation (24). Suggested mechanisms of protection are
immune exhaustion due to high antigen burden, chimerism,
and T cell deletion within the liver (23, 24). Chimerism refers
to the presence of donor cells within the recipient’s circulation
and occurs due to cell migration from the graft (23, 25).
Hematopoietic and T cells from the liver allograft migrate into
the recipients circulation and if donor cells comprise more
than 1% of the tissue it is referred to as macrochimerism, if
they comprise <1% it is known as microchimerism (23). The
persistence of chimerism has been associated with less rejection
and is postulated to have a role in tolerance induction (25). T-
cell deletion is suggested to occur within the liver due to direct
contact with parenchymal cells (23). It has been suggested by
Abrol et al. that the tolerance inducing effect of the liver in
combined liver-kidney transplantation is due to a cell type from
within the donor liver migrating to the other transplanted organ
and inducing immune regulatory effects (23).
FIGURE 1 | Different types of liver allografts. * DCD grafts not split. † Living donation of whole liver only possible with domino transplantation. ‡ Either of these grafts is
suitable for an auxiliary transplant.
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THE DIFFERENT TYPES OF LIVER
TRANSPLANT ALLOGRAFTS
The first liver transplant recipient to survive more than 24 h
following the procedure was a 19-month-old infant who received
a whole liver graft obtained from a 18-month-old brain dead
donor (26). This pivotal procedure was performed by Thomas
Starzl and his team in 1967 and subsequently numerous different
types of liver grafts have been utilized by transplant clinicians.
The main initial distinction between grafts is whether they were
obtained from a deceased or living donor (Figure 1).
A liver obtained from a deceased individual is known as a
deceased donor graft and depending on the terminal event, these
donors can be considered to have experienced brain death (DBD)
or circulatory death (DCD). The universal definition of brain
death is “The irreversible loss of the capacity for consciousness,
combined with irreversible loss of the capacity to breathe
and therefore irreversible cessation of the integrative function
of the brainstem” and strict neurological criteria need to be
satisfied to make this diagnosis (27). DBD donors therefore have
spontaneous cardiovascular activity providing organ perfusion
and are receiving mechanical ventilation, both of which are
maintained until cold perfusate is administered to the graft.
DCD donors are individuals who do not meet the strict brain
death criteria but are receiving life sustaining treatment that
is deemed to provide no overall benefit. In this scenario the
organ support is withdrawn, and death is determined by the
standard cardiorespiratory criteria. Therefore, DCD donation
involves a period of circulatory arrest with resultant ischaemia
prior to cold perfusion of the graft. This is known as the
donor warm ischaemic time (dWIT). The modified Maastricht
criteria (Table 1) is used to sub classify the DCD donors based
on the time of expected dWIT, and safety of organs used in
transplantation (28). Deceased donor grafts can be implanted
as whole or split grafts. Splitting of a cadaveric graft in most
instances would provide an extended right lobe graft to an adult
and a left lateral section to a pediatric recipient. Due to supply
not meeting demand, the use of grafts from cadaveric donors
with suboptimal features are known as extended criteria donors
(ECD) (29). These include advanced donor age, graft steatosis
and a DCD donor which are all features associated with poorer
transplant outcomes (29).
Living donor liver transplantation (LDLT) occurs when a live
individual undergoes a partial hepatectomy and donates this
portion of their liver. The type of hepatectomy will depend on
the volume of parenchyma the recipient requires. The donor
can be either biologically related or biologically unrelated. All
living donor grafts will be partial grafts, the only exception
to this would be when “Domino” transplantation occurs. A
“Domino” transplant occurs when recipient A undergoes a
total hepatectomy and this explanted liver is transplanted
into recipient B, recipient A can survive as they receive a
separate cadaveric or living donor graft (30). This strategy is
possible when recipient A suffers from one of several hereditary
metabolic diseases as these livers are otherwise normal. Familial
Amyloid Polyneuropathy is themost common reason for domino
liver transplantation (30). An auxiliary liver transplantation




IA Unexpected cardiac arrest out of
hospital without attempted
resuscitation






IIA Unexpected cardiac arrest out of
hospital with unsuccessful
resuscitation





Expected, planned cardiac arrest
after withdrawal of care
Category IV—Cardiac
arrest whilst brain dead
(Uncontrolled, controlled)
Sudden cardiac arrest following
brain death but prior to planned
organ recovery
Categories used to classify donation following cardiac death (22).
is another type of graft in which either a remnant or the
entire native liver is left within the recipient (31). Auxillary
transplantation is most commonly used in the setting of acute
liver failure as a “therapeutic bridge” until the native liver
regenerates (31).
POST REPERFUSION SYNDROME AND
PRESERVATION-REPERFUSION INJURY
An intense inflammatory response occurs immediately post OLT
due to multiple factors including surgical stress, tissue trauma,
preservation-reperfusion injury (PRI), blood loss and alloantigen
recognition. Traditionally the liver grafts are preserved ex-situ in
cold storage, thus without perfusion or oxygen delivery. These
preservation conditionsminimize oxidative phosphorylation and
reduce metabolic activity to ∼10% of the normal rate, the
energy of which is mainly derived by anaerobic metabolism (32).
In addition to ischaemia, hypothermic preservation conditions
have a deleterious effects on the cell organelles, cytoskeletons
and membranes (33). Re-establishment of blood flow results
in the release of reactive oxygen species (ROS) from the
mitochondria which in turn cause the release of proinflammatory
cytokines from Kupffer cells (34, 35). This predominantly innate
immune response is known as PRI and is also characterized
by liver sinusoidal endothelial cell (LSEC) dysfunction (35).
Intraoperative cardiovascular instability can occur immediately
following re-establishment of blood flow due to a large efflux
of metabolic substrates from the damaged liver, this entity is
known as postreperfusion syndrome (PRS) (36). Release of
cytokines (Tumor necrosis factor-α, IL-1, Interferon-γ, tumor
necrosis factor-β) results in the accumulation of neutrophils
(35). Previous literature has suggested that the immunogenicity
of the graft is increased with PRI due to interactions between
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the innate and adaptive immune system (37). Enhanced T-
cell priming is thought to result from this interaction and
contribute to both acute and chronic rejection (37). Advanced
donor age, graft steatosis and prolonged cold ischaemic time
are associated with more severe PRI manifestations (38). PRI
has physiological consequences and is considered the main
cause of primary non function (PNF) and delayed graft
function (DGF) (34, 39). In livers with severe PRI, ∼40%
will manifest PNF (40). Figure 2 further demonstrates how
the different events in the transplant process relate to the
immune response.
The human immune system is commonly divided into
innate and adaptive components with separate effector cells and
activation pathways. However, evidence suggests third division
of the immune system referred to as “innate-like” exists and
is comprised of both B and T lymphocyte subsets (41). A
characteristic of these cells is a rapid and robust response to
antigens with limited memory capabilities (41). Natural Killer
T cells (NKT) are one type of innate-like cell that is present in
the liver sinusoids and has been implicated in the transplant PRI
process (42). NKT cells are subclassified into type I and type II
based on the expression of invariant TCR-α and minimal TCR-
β (Type 1) in comparison to diverse TCR-α and TCR-β (type II)
(42). In a murine experimental model of PRI, type I NKT cells
were found to induce injury and with an increased intracellular
expression and secretion of IFN-γ. Type II NKT were shown
to be protective against PRI and the proposed mechanism was
that they inhibit the pro-inflammatory effects of type I NKT
cells (43).
LIVER ALLOGRAFT REJECTION
Acute T-cell mediated rejection (TCMR) is the most common
immune mediated complication following liver transplantation
(44). Less frequent immune complications are recurrence of an
AILD, plasma cell rich rejection, antibody mediated rejection
(AMR) and unresolved TCMR/AMR progressing to chronic
rejection. Allorecognition of transplanted tissue is known to
occur via three pathways; direct, indirect and semi-direct (45).
The direct pathway involves the recipients T-cells recognizing
the donor MHC molecules on donor antigen presenting cells
(APCs). The indirect pathway occurs when the donor antigen
is processed by recipient APCs and recipient MHC molecules
expressed. The semi direct pathway involves cell exchange
either via exosomes or the process of trogocytosis, which is the
active transfer of plasma membrane fragments from an antigen
presenting cell to a lymphocyte via cell conjugation (45, 46).
The semi-direct pathway is yet to be completely understood
but it is believed to involve the transfer of complete MHC-
peptide complexes from donor APCs to recipient APCs. This
results in a recipient APC displaying both a self and donor
MHCmolecule, both with an attached donor antigen. This brings
both the direct and indirect pathway together onto a single
APC and allows additional interaction between the two CD-
4 or CD-8 T-cells that bind with each MHC:peptide complex,
therefore forming a 3 cell model (45). All pathways lead to
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which induce T-cell proliferation. The initial alloreactive T
cell response is driven by the direct pathway with the
indirect pathway assuming the main role as time progresses
(8, 45).
The diagnosis of graft rejection is made via liver biopsy
and graded in severity via the Banff criteria (47, 48). In
addition to criteria for typical TCMR and chronic rejection,
the 2016 update of the Banff working group recognized what
had previously been termed de novo autoimmune hepatitis
as a form of plasma cell rich rejection and added criteria
for the diagnosis of acute and chronic AMR (48). Modern
immunosuppressive agents have resulted in a reduction of
early acute rejection from 60 to 33.5% (49, 50). This finding
concurs with other authors that reported TCMR to occur most
commonly in the early post-transplant period (47). Early TCMR
is a result of the direct alloantigen presentation pathway and
is characterized by pleomorphic portal inflammation, bile duct
injury and the lack of necro-inflammatory interface activity (48).
The indirect alloantigen presentation pathway is thought to
result in the late TCMR and has predominantly mononuclear
portal inflammatory change, less subendothelial inflammation
than early TCMR but more interface and necro-inflammatory
perivenular activity (48, 51). Early TCMR generally responds
to treatment and graft loss as a result is reported to be <1%
(52). Late TCMR is less responsive and a preceding episode of
moderate-severe early TCMR has been identified as a risk factor,
however Jadloweic et al. reported more than half of the patients
who experience late TCMR had no history of early TCMR (49).
The implications of late TCMR are more sinister with a higher
rate of graft loss due to chronic rejection or cholestasis (49).
Chronic rejection occurs relatively rarely with a reported rate
of 3–5% following liver transplant (53). Chronic rejection is
defined as 50% bile duct loss and/or a foam cell arteriopathy, it
typically occurs early following non-responsive acute rejection,
and is increasingly recognized to have an antibody mediated
component (48, 53).
Acute AMR causes graft dysfunction due to donor specific
antibody (DSA) interaction to antigens on the graft. DSAs
may be pre-existing (preformed) or develop post-transplant in
response to foreign antigen (de novo antibodies). DSAs may be
against HLA antigens, which are the most readily detected by
current assays, or non-HLA antigens such as anti-glutathione
S transferase (GSTT-1) and anti-angiotensine 2 receptor (54,
55). The development of anti GSTT-1 antibodies has been
demonstrated to occur in recipients who are negative for the
GSTT-1 gene but receive a graft from a GSTT-1 positive
donor (55). These anti-GSTT1 antibodies have been shown to
be pathogenic and are implicated in periportal inflammation,
fibrosis and the loss of bile ducts (55). The understanding of
AMR is evolving, it is also believed to often occur concurrently
with ACR. The liver exhibits strong ABO and MHC I antigen
expression on all liver cells in normal circumstances, however
the MHC I expression on hepatocytes is weaker (56). Liver
allografts in comparison to kidneys are highly resistant to
HLA alloantibodies and numerous mechanisms are proposed to
explain this phenomenon (57). Secretion of soluble HLA class
1 molecules which form immune complexes with alloantibodies
and then subsequently undergo clearance by Kupffer cells is one
such mechanism (57). Davies et al. demonstrated that the liver
graft also continues to deliver HLA class I antigens into the
recipients serum for the lifetime of the graft, thus generating
called DSAs (58). Resistance to AMR is also enhanced by the
fenestrated endothelium of the sinusoidal network as occlusion
by activated immune complexes does not result in the same
degree of ischaemia as other transplanted organs (23). The
main clinical manifestations are graft dysfunction, transaminitis,
and thrombocytopenia (48). The histological changes that occur
are oedema, endothelial cell swelling, leukocyte sludging or
margination and vascular deposition of tissue complement
component 4d (C4d) (48). The catastrophic Vasculitis and
intravascular thrombosis associated with hyperacute rejection
of renal allografts is exceedingly rare following liver transplant
(44, 59). Approximately 13% of liver transplant recipients have
persisting DSA positivity and the most commonly found is
the anti-HLA class II DSAs (60, 61). Del bello et al. found
in a cohort type study that 5 of out the 21 subjects with de
novo DSA formation experienced acute AMR and the average
liver fibrosis score was higher in this subjects with DSAs
(60). This latter finding is similar to previous authors who
have associated DSA positivity with progressive fibrosis, graft
loss and poorer patient survival (48, 61). Anastomotic biliary
strictures have also been associated with the presence of anti-
HLA class II DSAs in patients who have undergone ABO
compatible transplantation (62). Rationale for this observation
is that biliary structures receive their entire blood supply from
the peri-biliary capillary plexus and therefore is not protected
from occlusion by immune complexes in the same manner as
the hepatic sinusoids (23). Establishing the histopathological
evidence for the entity of chronic AMR is frequently challenging
due to confounding factors (48). The Banff working group
has established criteria for probable and possible chronic
AMR. The histology findings associated with chronic AMR are
low levels of portal, periportal, perivenular lymphoplasmacytic
inflammation and interface necro-inflammatory activity with
non-inflammatory fibrosis (48).
THE IMMUNE RESPONSE TO CADAVERIC
GRAFTS
During the initial decades of OLT, only cadaveric grafts from
DBD donors were utilized. DCD programs emerged to expand
the organ donor pool and consequently reduce waitlist mortality
(63). At present, nearly a third of organ donations in the UK
occur following DCD and the proportion of liver transplants
utilizing DCD organs increased from 6.3% in 2005 to 26.3% in
2010 (64, 65). The inferior outcomes of DCD liver grafts was their
higher rate of of PNF, non-anastomotic biliary complications,
graft loss and poorer overall survival (65). However, the
complication profile has changed over time with increased
experience. Ischaemic injury occurs to the biliary epithelium
during the dWIT making these grafts more susceptible to
ischaemic cholangiopathy (65). It has been demonstrated that
DCD grafts experience a more severe PRI with greater elevation
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of alanine transaminase (AST) and cell death (66). This may
result in the devastating consequence of primary non-function
(67). Despite DBD donation avoiding a period of circulatory
arrest and subsequent warm ischaemia, significant detrimental
changes are already thought to have occurred within the graft as
a result of brain death. The physiological changes that take place
during brain death have been described as an “autonomic storm”
with initial intense parasympathetic response followed by short
lived sympathetic activation (68). The decline in sympathetic
activity is accompanied by myocardial depression and at all
stages of this process the liver is subjected to an ischaemic
type injury (68). In addition, there is widespread activation
of inflammatory mediators irrespective of any hemodynamic
instability (69).
An experimental animal study utilizing a rat model
investigated the differing proinflammatory (TLR4, HMGB1,
IL-1β, IL-6, TNF-α, MCP-1, E-selectin, and P selectin)
cytoprotective (HO-1, VEGF, Hif-1α) and injury gene (P21,
Bax, Bcl-2) expression associated with DCD and DBD grafts,
utilizing a living donor liver as a reference (70). Directly after
organ retrieval, DBD grafts demonstrated a down regulation of
TLR4 but an upregulation of IL-6 (326-fold), IL-1β (15-fold),
TNF-α (22- fold), P-selectin (41.7-fold), and E-selectin (12.9-
fold) in comparison to LD grafts (70). The DCD livers only
demonstrated an increase in HMGB1 directly after retrieval,
in comparison to the living donor group. In addition, HO-1
expression increased to a larger extent in the DBD (12-fold)
than the DCD (5.6-fold) livers in comparison to the living donor
liver. As indicated by gene expression, the DBD and DCD grafts
responded differently a period of cold ischaemia. After 12 h of
cold ischaemia, the DBD livers inflammatory gene expression
did not change significantly from immediately post retrieval.
However, DCD Livers demonstrated a 4-fold increase in IL-6,
30-fold increase in MCP-1 and 4-fold increase in E-selectin
in comparison to living donor grafts (70). The pro-apoptotic
gene Bcl-2 increased significantly (4.6-fold) in the DCD livers
in comparison to both DBD and liver donor livers. DBD livers
showed a further 17-fold increase in HO-1 gene expression after
a period of cold ischaemia in comparison to the living donor
grafts. These findings demonstrate a pronounced inflammatory
process is occurring in the liver at the time of retrieval in DBD
livers, likely as a result of the physiological and inflammatory
changes that occur during brain death. It was proposed that
not enough time had elapsed following the short but significant
period of warm ischaemia in the DCD livers to see a significant
increase in inflammatory and apoptotic genes at the time
of retrieval.
A recent cohort study that compared DCD and DBD grafts
demonstrated equivalent outcomes in regards to primary non-
function, acute cellular rejection, need for retransplantation and
patient survival at 3 years (71). Pitarch Martinez et al. (71)
demonstrated an acute cellular rejection rate of 20% in DCD
and 16.4% in DBD grafts that was not statistically significant
(P = 0.685) (71). However, in this cohort the DCD grafts
needed to meet strict criteria (Maastricht III, WiT <30min,
Donor age ≤65) and their recipients had lower MELD scores.
Doyle et al. performed a similar cohort type study and had
similar findings with the rate of rejection being 24.5 and
26.5% in the DCD and DBD group, respectively (P = 0.84),
the early rejection rate (≤30 days) was identical (72). A case
matched study by Pine et al. comparing DBD to DCD grafts
also demonstrated a similar rate of both acute and chronic
rejection however primary non-function was higher in the DCD
group (2/39 vs. 0/39) (73). PRI is thought to be increased
in DCD grafts and this has been demonstrated by a greater
elevation in early post-operative transaminases (74). Despite
innate immunity being the main driver of PRI, it has been
suggested that this is positively correlated with subsequent graft
rejection (75). Mechanisms for this include trafficking of DCs
into the graft and enhanced T cell priming (37). The results
of the aforementioned clinical studies have not demonstrated
this effect.
A study by Xystrakis et al. investigated the frequency and
function of T-cell subsets in liver perfusate fluid obtained from
DBD, DCD and living donors. The perfusate fluid was obtained
from the graft at the end of the cold storage period and was
analyzed by flow cytometry, cell sorting and culture (76). The
frequency of memory and naïve T-cell subsets in the perfusate
did not differ between all graft types but the frequency of
CD69+ CD8 T-cells was significantly higher in the perfusate from
DBD grafts (76). In addition, the proportion of IL-2 and IFN-γ
produced by CD8T-cells was higher inDBD grafts. These authors
concluded that the process of brain death is associated with the
release of non-specific inflammatory mediators (76). Jaseem et al.
compared immunohistochemical findings of preimplantation
liver biopsies from living and deceased (DBD) donor grafts (77).
Significantly higher levels of CD3+ lymphocytes and Kuppfer
cells were found in the DBD grafts. In addition, the adhesion
molecule ICAM-1 was found to be expressed at higher levels in
the DBD grafts (77). A higher percentage of CD3+ lymphocytes
in the preimplantation biopsy was associated with subsequent
acute rejection in the DBD graft recipients (77). These authors
concluded that the process of brain death resulted in a significant
increase in inflammatory cell recruitment and migration into the
liver allograft in comparison to living donor grafts. However,
clinical outcomes of the recipients did not differ (77).
The literature describing humoral responses in ABO
compatible DCD grafts is sparse. Levitsky et al. (78) compared
the differences of both preformed and de-novo DSAs in living
donor with deceased donor recipients, however the results for
DCD and DBD subgroups were not published (78). This study
did not demonstrate a difference in either preformed or de-novo
DSA formation in either graft group. The presence of DSAs,
either preformed or de-novo, did not affect patient survival in
either graft group but did affect the graft survival (78). The
deceased donor recipients with de-novo DSAs had higher rates
of graft failure (P = 0.005) (56). Coexisting TCMR or recurrent
viral hepatitis is thought to increase the DSA mediated damage
as inflammation within the liver increases MHC I expression
and induces MHC II expression. As previously mentioned, DSAs
can be directed at either of these MHC molecules. Inlet and
mononuclear septal venulitis have been suggested as the cause of
the interface hepatitis that occurs with the presence of de novo
DSA formation (56).
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THE IMMUNE RESPONSE TO LIVING
DONOR GRAFTS
The lack of suitable deceased donor livers for transplantation and
the associated waitlist mortality has prompted the development
of living donor liver transplantation (LDLT). The first successful
LDLT was performed in Australia in 1989, a female adult donated
her left lobe and it was implanted into her to 17-month-old
son who suffered from biliary atresia (79). Following this pivotal
event, LDLT has been performed around the world and at present
one third of pediatric liver transplants involve a living donor
(80). Particular political, cultural and religious beliefs in Asian
countries have resulted in very low rates of deceased donors but
the highest rates of LDLT (81, 82). Initially, LDLT procedures
were limited to adult-pediatric with left lateral segment grafts
(81). Significant progress has occurred and at present adult-
adult LDLT with right lobe grafts are now being performed
(81). LDLT is technically challenging as the graft must have
an adequate volume of parenchyma, portal and arterial inflow,
venous outflow and biliary drainage. The transplantation of a
substantially smaller hepatic allograft in LDLT puts the recipient
at the additional risk of small-for-size-syndrome (SFSS) (82).
Other additional risks inherent with LDLT are the surgical risks
posed to the donor (83). Inference based on the experience from
living donor kidney transplantation would suggest that LDLT
would have superior immunological outcomes, however this is
yet to be conclusively demonstrated (84).
In the United states, adult-to-adult LDLT is increasing in
frequency with a 82% graft survival at 1 year and a 10 years
overall survival post-transplant that exceeded deceased donor
transplantation (70 vs. 64%) (83). Avoidance of a graft exposed
to the physiological perturbations of brain death and minimal
cold ischaemic time are both thought to reduce the initial
inflammatory response and subsequent immune activation. In
addition, there may be HLA matching between genetically
related donors and recipients (84). The evidence regarding the
immunological benefits of adult-to adult LDLT is conflicting
at present. Shaked et al. demonstrated in their retrospective
review a similar rate of biopsy proven acute cellular rejection,
more recurrent episodes and more frequent graft loss as a
result in LDLT in comparison to deceased donor transplants
(84). Subsequent to this, Levitsky et al. demonstrated that the
incidence of acute cellular rejection was significantly lower in
LDLT patients who received a graft from a biologically related
donor in comparison to a non-biologically related and deceased
donors (85). Another pertinent finding from this study relating to
all liver transplant recipients was that an episode of biopsy proven
cellular rejection significantly increased the patients risk of
subsequent graft loss and death. The humoral immune response
following LDLT has also been investigated by Levitsky et al.
(78) and these authors found no difference in preformed or de
novo donor specific antibody formation in LDLT in comparison
to cadaveric graft recipients (DSA) (78). It was demonstrated
however that de novo DSA positivity was associated with
higher graft failure in both LDLT and cadaveric graft recipients
and this relationship was proportional to the quantity of
DSA present.
Experimental data indicates that inflammatory cell and
cytokine concentrations are significantly lower in living donor
grafts prior to retrieval, reperfusion and post reperfusion in
comparison to brain death donors (68). Liver biopsies taken at
various timepoints during the retrieval and transplant procedure
by Weiss et al. (68) demonstrated that the mRNA concentration
of CD3 and CD25 to be significantly lower in LDLT grafts in
comparison to those fromDBD donors. These authors concluded
that although the presence of immune cells and cytokines
increase as the LDLT procedure progresses, the level of immune
activation is far less intense than that in transplants with DBD
grafts (68). Interestingly, the LDLT recipients in this study had
significantly lower transaminases in the post-operative period
compared with DBD recipients which signifies a milder PRI.
These authors also demonstrated a lower incidence of biopsy
proven rejection in the 24 months post-transplant for LDLT in
comparison to DBD graft recipients (38 vs. 28%, P = 0.04) (68).
De Jonge et al. performed biopsies on both cadaveric and living
donor grafts prior to retrieval (PRE), following cold perfusion
(COLD) and post reperfusion in the recipient (POST) (86).
Gene expression was analyzed and there was an upregulation
of inflammatory genes between the PRE and POST biopsy in
the cadaveric grafts, these included genes for IL-8 and ICAM-
1. In the living donor grafts there was also an upregulation of
genes for SOCS3, Hepatocyte growth factor (HGF) and NFκB1
from the PRE to the POST reperfusion sample and these are all
associated with regeneration (86). The parenchymal transection
during living donor procurement may be the initiating stimulus
for this. There was also upregulation of MHC II genes in the
living donor grafts and it was suggested that smaller grafts are
associated with increased alloreactivity (86).
ABO INCOMPATIBLE GRAFTS
Transplanting organs across the ABO blood groups has for a
long time been associated with poor outcomes due to increased
graft loss and worse patient survival (87). The blood antigens
are expressed on hepatic vasculature, biliary epithelium and
hepatocytes and all are a target for AMR. Despite knowledge of
these reactions and the inferior results, a compatible graft may
not be available and an emergency situationmay necessitate ABO
incompatible transplant to prevent certain death (88). Since its
initial inception, numerous immune modulating strategies and
therapies have been implemented and a recent meta-analyses
found no difference in patient survival following an ABO
incompatible in comparison to an ABO compatible transplant
(89, 90).
Acute AMR is a feared consequence of ABO-I liver
transplantation and can often lead to loss of the graft. Numerous
interventions have been attempted to mitigate the risk of AMR
and these include; preoperative plasmapheresis, splenectomy,
local infusions, mycophenolate mofetil, and rituximab (91)
Several studies have failed to demonstrate a correlation between
preoperative ABO antibody titer and AMR (92). It has been
the implementation of rituximab, an anti-CD20 monoclonal
antibody that has yielded the greatest improvement in outcomes
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(92–94). Commonly used AMR prophylaxis regimes include a
single dose of Rituximab 2–3 weeks prior to transplantation
(92, 94). Plasmapheresis aims to reduce the ABO antibody titer
and is commonly performed both prior to transplantation and
post operatively, however the antibody titer level targeted with
this modality varies between institution (92). Undertaking a
splenectomy on the recipient at the time of transplantation
initially gained acceptance as this organ is the site of antibody
production and harbors a large amount of B cells and plasma cells
(92). However, studies have failed to demonstrate a benefit from
this procedure, especially following the introduction of rituximab
(92, 93).
Acute AMR in the ABO incompatible graft can result
in graft failure via two types of injuries; liver necrosis in
the first 1–2 post-operative weeks or diffuse intra-hepatic
bile duct injury in the subsequent 2–3 months (92). These
injuries are thought to occur because the hepatic vascular
endothelium and biliary epithelium exhibit ABO antigens and
therefore are sites for antibody-antigen binding with subsequent
complement activation, cytokine production, cell migration and
thrombus formation (93). The biliary damagemanifests as diffuse
biliary strictures and can result directly from the antibody-
antigen reaction or secondary to ischaemia from intrahepatic
arterial thrombosis (ischaemic cholangiopathy) (94). Song et al.
compared outcomes in a cohort of patients that underwent either
ABO compatible LDLT or ABO incompatible LDLT following
the introduction of Rituximab in the desensitization protocol
(94). The difference in patient survival, biopsy proven TCMR and
post-operative LFTs were not significant. Biliary strictures were
more common in the ABO incompatible group (20.7 vs. 14.2%, p
= 0.038) with non-anastomotic biliary strictures occurring in 12
(8.5%) of the ABO incompatible recipients. Interestingly, all 12
underwent liver biopsy and only one case had histopathological
evidence of AMR. No recipient of an ABO compatible graft
developed a non-anastomotic biliary stricture (94).
IMMUNE RESPONSE IN THE PEDIATRIC
PATIENT
The outcomes of pediatric liver transplantation have improved
significantly over the last several decades and a 2012 study
demonstrated a 1 and 10 years survival of 95 and 88%,
respectively (95, 96). The indications for transplantation differs
in the pediatric population with the most common indication
in the US being biliary atresia (95, 97). In contrast to adults,
transplantation for viral hepatitis andmalignant tumors are a rare
occurrence. Approximately 8% of liver transplants each year in
the US are performed on children with an equal portion receiving
either a whole or split graft (98). A large Canadian transplant
center reported LDLT to comprise 46% of all pediatric LT. The
same authors reported that the LDLT grafts comprised the left
lateral section, left and right lobe in 82.8%, 3.7% and 13.4%
respectively between 2000 and 2015 (99). Operational tolerance,
post-transplant lymphoproliferative disorder (PTLD) and graft
fibrosis occur more commonly in this patient population.
An individual’s immune system needs to rapidly adapt as
it makes the transition from intra-uterine life to the antigen
rich outside world (100). Initially there is a heavy reliance on
innate mechanisms, with maturation of the immune system
gradually occurring as we progress through childhood. Acute
cellular rejection is a common occurrence in this population
with reported incidence of up to 60% (95). In a retrospective
cohort study of 46 children who received a split graft from a
living relative, 44 episodes of ACR occurred over 10 years of
follow up with 35 of these in the first 6 weeks post op (101).
It is believed that younger children (<1 year of age) are more
likely to become immunologically tolerant of their graft, but
the mechanism is yet defined (102, 103). Byun et al. compared
outcomes of pediatric recipients that underwent OLT at <12
months of age with those older than 12months and found the rate
of ACR to be similar (30.2 and 33.0%, P = 0.848) in each group
(104). This differs from a previous study utilizing the SPLIT
database which demonstrated the rate of ACR in those <12
months was significantly less than in older pediatric recipients
(0.20 vs. 0.44 episodes per patient-year, P = 0.001) (105). A large
retrospective cohort study by Talisetti et al. assessed numerous
factors and their relationship with operational tolerance (106). A
recipient age of <12 months was the only variable significantly
associated with a higher rate of developing operational tolerance
(106). It has been demonstrated that in early infancy the Th2
cytokines (IL4, IL10) predominate over the Th1 cytokines (IL-
2, IFN-γ) and this may contribute to graft acceptance in this
age group (107). This is supported by the fact that pediatric
patients that experienced TCMR had a higher proportion of Th1
cytokines (107).
Post-operative frequency of TREGs and IL-4 are higher in
pediatric recipients who receive a LD graft in comparison to a
deceased donor graft cadaveric (108). Favorable immunological
outcomes would be expected as TREGs and IL-4 are both
associated with immunotolerance, however the clinical evidence
is less clear. In the retrospective cohort study published be Kehar
et al. compared TCMR rates between pediatric LD and deceased
donor recipients. The 1, 3 and 5 years TCMR rejection free
survival was 64.4%, 61.1%, and 61.1% for LD and 55%, 44.4%,
and 43.4% for cadaveric graft recipients respectively, however
this difference was not statistically significant (P = 0.08) (99).
Alonso et al. found that the incidence of rejection was the same
in pediatric cadaveric graft compared to LD recipients (78 vs.
74%) but there was a higher rate of steroid resistant rejection
in the cadaveric graft group (43 vs. 13%, P ≤ 0.01). Kehar et al.
found no difference in rejection rates between pediatric patients
that received a graft from a genetically related compared with
unrelated donor (P = 0.4) (99).
IMPLICATIONS FOR CLINICAL PRACTICE
There is variation in both the standard post-operative
immunosuppression and rejection treatment regimens utilized
by transplant centers around the world. The immunosuppressant
drug most commonly used long term is the calcineurin inhibitor,
tacrolimus, based on evidence of improved efficacy (109, 110).
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There does not appear to be clinical evidence that altering
standard immunosuppressive regimes based on the type of
graft is beneficial, the only exception to this would be the
implementation of pre-operative Rituximab infusions for ABO-I
transplants. Pediatric patients that are transplanted at <12
months of age appear to have a more immunotolerant profile.
This should be considered when planning transplantation
for their native liver disease as it may optimize graft survival
and minimize morbidity from immunosuppression. The
inflammatory insult on the hepatic allograft that occurs during
the period of brain death is undeniable. Administration of
corticosteroids to the donor prior to organ retrieval has been
investigated in a randomized controlled trial but provided
no benefit (111). Further research is needed in this area
as it may improve outcomes and result in the increased
utilization of grafts. The desire to minimize graft injury
during the preservation period has led to the development of
machine perfusion strategies such as hypothermic (HMP) and
normothermic machine perfusion (NMP). A recent randomized
controlled trial of NMP demonstrated increased organ utilization
and a reduction in preservation-reperfusion injury, as evidenced
by a significant reduction in post-operative LFTs (112).
Administration of anti-inflammatory and immune mediating
therapies directly to the hepatic allograft via the machine
perfusion circuit is a growing area of research interest (113).
Tolerance inducing therapies are showing promising results
in clinical studies. In a landmark pilot study, Todo et al. showed
that a single post-operative infusion of TREG cells allowed
accelerated withdrawal of immunosuppression at 6 months
post LDLT and 70% of these individuals achieved operational
tolerance (114). The patients that experienced rejection in
this pilot study were transplanted for AILD, suggesting that
these individuals may require additional strategies (114). This
study utilized recipient TREG cells that were co-cultured
with irradiated donor leukocytes obtained several weeks before
transplantation, an opportunity that does not exist in the
deceased donor transplantation setting. The participants also
underwent splenectomy at the time of transplantation. Sanchez-
Fueyo et al. recently published results of a phase 1 clinical trial
investigating the safety, applicability and biological activity of
treg administration post cadveric liver transplantation (115). The
treg cells in this study are autologous and not exposed to donor
antigens during the culture process Subjects in this study received
a doses of either 0.5–1 or 3–4.5 million tregs/kg. Nine subjects
were enrolled and only a single subject who received the higher
dose experienced a transfusion reaction (115). The frequency of
tregs in the peripheral blood of subjects who received the higher
dose remained elevated for 1 month and this likely reflected the
infused tregs as the subpopulation that increased was similar
to the infused cells (115). Although it did not reach statistical
significance, donor specific hyporesponsiveness in the group that
received the larger dose of tregs was observed (115). Tregs exert
their suppressive effects on multiple different immune cells via
both direct and indirect mechanisms (116). Direct mechanisms
include IL-10, IL-35, TGF-β, secretion which results in apoptotic
cell death of target effector cells. Depletion of extracellular
ATP and IL-2 via the expression of CD39/CD73 and CD25,
respectively, are examples of the indirect mechanisms (117).
Other tolerance inducing therapies currently under investigation
include Dendritic Cells, IL-2 and regulatory macrophages.
Their rationale and current place in clinical transplantation are
outlined elsewhere (118, 119).
CONCLUSION
The field of liver transplantation has advanced significantly
since the 1960’s. Progress has been made in organ preservation,
post-operative care, immunosuppression and optimal utility
of different grafts to ensure those in need get the best
possible access to this lifesaving procedure. Grafts previously
not possible such as ABOi LDLT are now commonplace
in many centers with acceptable results. Based on existing
literature, a similar immune response is elicited to the
majority of grafts following implantation, comprising an
initial innate inflammatory response due to preservation-
reperfusion mechanisms followed by a predominantly cell
mediated response. However, contribution from the innate-like
and humoral components of the immune system to PRI and
graft rejection are becoming increasingly recognized. Grafts
from brain dead donors appear to have a higher inflammatory
cell infiltrate and cytokine concentration at retrieval than
DCD or living donor grafts, however clinical differences in
rejection as a result are not evident. It is likely that both
cell and antibody mediated injury results in the morbidity
associated with chronic rejection. Acute TCMR is common
following OLT but undergoing transplant in the first year of
life seems protective. Hyperacute graft rejection of the liver is
exceedingly rare. Strong clinical evidence that a DBD, DCD or
LDLT graft is associated with a lower rate of TCMR is not
apparent. Research into tolerance inducing therapies has shown
promising results and the results of larger, phase II trial are
eagerly awaited.
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